CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our portfolio represents the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections.
“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”
— Tim Jinks, Head of Infectious Diseases Interventions, Wellcome Trust. Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.